Director of the Shanghai Institute of Pediatric Medicine, Chief Physician, Level 2 Dr., Doctoral Supervisor, Director of the Shanghai Children's Rare Disease Diagnosis and Treatment Center, and Head of the National Key Clinical Specialty of Pediatric Surgery
Affiliated HospitalXinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
→
He is the Third Chairman of the Chinese Society of Parenteral and Enteral Nutrition, the Seventh and Eighth Vice Chairman of the Chinese Society of Pediatric Surgery, and the Vice President of the Chinese Nutrition Society. He was among the first in China to successfully implement intestinal rehabilitation treatment for neonatal short bowel syndrome, developing a three-stage intestinal rehabilitation treatment plan for short bowel syndrome. He has treated nearly 200 children with short bowel syndrome from across the country, achieving an overall survival rate of 86.5% after treatment, reaching international advanced levels. He presided over the development of my country's first "Clinical Application Guidelines for Neonatal Nutritional Support in China" and "Consensus on Short Bowel Syndrome in China," and was invited to participate in the joint revision of the 2016 edition of the "Guidelines for Pediatric Parenteral Nutrition" by the European Society for Pediatric Gastroenterology, Hepatology and Nutrition. In 2024, the hospital prescribed the first innovative drug in China, teduragutide, for the treatment of short bowel syndrome, potentially freeing children from long-term intravenous infusion dependence. He has presided over 7 national-level research projects, including key projects of the National Natural Science Foundation of China, and published 185 SCI papers as the first author or corresponding author. He has also received 9 provincial and ministerial-level awards, including the second prize of the National Science and Technology Progress Award, as the first author.